EP3253797A4 - Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof - Google Patents

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof Download PDF

Info

Publication number: EP3253797A4
Authority: EP; European Patent Office
Prior art keywords: chemokine; compositions; making; fusion polypeptides; immunoglobulin fusion
Prior art date: 2015-02-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16747125.9A

Other languages

German (de)

French (fr)

Other versions

EP3253797A1 (en

Inventor

James W. Lillard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jyant Technologies Inc

Original Assignee

Jyant Technologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-03

Filing date

2016-02-02

Publication date

2018-10-03

2015-02-03 Priority claimed from US14/612,884 external-priority patent/US9249204B2/en

2016-02-02 Application filed by Jyant Technologies Inc filed Critical Jyant Technologies Inc

2017-12-13 Publication of EP3253797A1 publication Critical patent/EP3253797A1/en

2018-10-03 Publication of EP3253797A4 publication Critical patent/EP3253797A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP16747125.9A 2015-02-03 2016-02-02 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof Withdrawn EP3253797A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14/612,884 US9249204B2 (en)	2011-06-01	2015-02-03	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
PCT/US2016/016191 WO2016126719A1 (en)	2015-02-03	2016-02-02	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Publications (2)

Publication Number	Publication Date
EP3253797A1 EP3253797A1 (en)	2017-12-13
EP3253797A4 true EP3253797A4 (en)	2018-10-03

Family

ID=56564605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16747125.9A Withdrawn EP3253797A4 (en)	2015-02-03	2016-02-02	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Country Status (3)

Country	Link
EP (1)	EP3253797A4 (en)
CN (1)	CN107207603A (en)
WO (1)	WO2016126719A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3737689A4 (en) *	2018-01-09	2021-12-01	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
FI3794024T3 (en) *	2018-05-14	2023-08-10	Werewolf Therapeutics Inc	Activatable interleukin-2 polypeptides and methods of use thereof
WO2019219029A1 (en) *	2018-05-15	2019-11-21	科济生物医药（上海）有限公司	Genetically engineered cell and application thereof
JP2022544785A (en) *	2019-08-13	2022-10-21	エルピス・バイオファーマシューティカルズ	Modified interleukin-2 receptor beta agonist
CN111440244B (en) *	2020-04-09	2021-03-16	诺未科技（北京）有限公司	Metastatic cancer vaccine targeting VEGFR2
CN113318120A (en) *	2021-06-07	2021-08-31	昆明医科大学第二附属医院	Application of miR4512 and CXCL2 in autoimmune diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005037305A1 (en) *	2003-10-16	2005-04-28	Applied Research Systems Ars Holding N.V.	Therapeutic uses of chemokine variants
US20070036750A1 (en) *	2005-08-12	2007-02-15	Schering Corporation	MCP1 fusions
US20100196406A1 (en) *	2007-06-04	2010-08-05	Rappaport Family Institute For Research In The Medical Sciences	Agents for the treatment of inflammatory diseases and methods of using same
US20120308565A1 (en) *	2011-06-01	2012-12-06	Morehouse School Of Medicine	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130323245A1 (en) *	2011-06-01	2013-12-05	Morehouse School Of Medicine	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150584A (en) *	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
PL2229956T3 (en) *	2004-09-13	2013-09-30	Genzyme Corp	Multimeric constructs
GB0605735D0 (en) *	2006-03-22	2006-05-03	Immunobiology Ltd	Composition and method for mediating an immune response

2016
- 2016-02-02 EP EP16747125.9A patent/EP3253797A4/en not_active Withdrawn
- 2016-02-02 CN CN201680007087.2A patent/CN107207603A/en active Pending
- 2016-02-02 WO PCT/US2016/016191 patent/WO2016126719A1/en active Application Filing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005037305A1 (en) *	2003-10-16	2005-04-28	Applied Research Systems Ars Holding N.V.	Therapeutic uses of chemokine variants
US20070036750A1 (en) *	2005-08-12	2007-02-15	Schering Corporation	MCP1 fusions
US20100196406A1 (en) *	2007-06-04	2010-08-05	Rappaport Family Institute For Research In The Medical Sciences	Agents for the treatment of inflammatory diseases and methods of using same
US20120308565A1 (en) *	2011-06-01	2012-12-06	Morehouse School Of Medicine	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130323245A1 (en) *	2011-06-01	2013-12-05	Morehouse School Of Medicine	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130330337A1 (en) *	2011-06-01	2013-12-12	Morehouse School Of Medicine	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016126719A1 *

Also Published As

Publication number	Publication date
WO2016126719A1 (en)	2016-08-11
EP3253797A1 (en)	2017-12-13
CN107207603A (en)	2017-09-26

Similar Documents

Publication	Publication Date	Title
EP3347472A4 (en)	2019-02-06	Compositions comprising cyp76ad1- clade polypeptides and uses thereof
EP3356308A4 (en)	2019-07-31	Calcium-silicate-based porous particles, composition, method of making and use thereof
EP3377307A4 (en)	2019-07-17	Structural composition and method
EP3455263A4 (en)	2020-01-01	Cd40l-fc fusion polypeptides and methods of use thereof
EP3354653A4 (en)	2018-08-29	Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
IL275435A (en)	2020-08-31	Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP3373910A4 (en)	2019-06-12	Echinomycin formulation, method of making and method of use thereof
EP3212290A4 (en)	2019-01-23	Serpin fusion polypeptides and methods of use thereof
EP3253797A4 (en)	2018-10-03	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
EP3300501A4 (en)	2019-04-17	Novel compositions, uses and methods for making them
EP3510134A4 (en)	2020-06-24	Cleaning composition, method of making and use thereof
EP3092248A4 (en)	2017-06-28	Fusion polypeptides and methods of use
EP3391897A4 (en)	2019-08-14	Hemostatic composition and hemostatic method using hemostatic composition
EP3337518A4 (en)	2019-06-12	Bag3 compositions and methods
EP3323825A4 (en)	2019-04-03	Polypeptide compound and preparation method and use thereof
EP3315508A4 (en)	2019-08-28	Polypeptide compound and preparation method and use thereof
EP3146968A4 (en)	2018-01-24	K2 composition, preparation method therefor, and application thereof
EP3202778A4 (en)	2018-04-25	Conotoxin polypeptide kappa-cptx-bt105, and method for preparation thereof and application thereof
EP3392263A4 (en)	2020-03-04	Polypeptide compound, preparation method therefor and use thereof
EP3349748A4 (en)	2019-05-08	Composition and methods thereof
EP3319930A4 (en)	2019-04-10	Methods and compositions for the stabilizaton of proteins
EP3394174A4 (en)	2019-08-07	Composition, method of making composition, and article
EP3394175A4 (en)	2019-08-07	Composition, method of making composition, and article
EP3132790A4 (en)	2017-11-22	Exenatide-containing composition and preparation method therefor
EP3202775A4 (en)	2018-02-28	Conotoxin polypeptide kappa-cptx-bt104, and method for preparation thereof and application thereof

Legal Events

Date	Code	Title	Description
2017-11-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-12-13	17P	Request for examination filed	Effective date: 20170629
2017-12-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-12-13	AX	Request for extension of the european patent	Extension state: BA ME
2018-05-09	DAV	Request for validation of the european patent (deleted)
2018-05-09	DAX	Request for extension of the european patent (deleted)
2018-06-27	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20180524BHEP Ipc: A61K 39/395 20060101ALI20180524BHEP
2018-10-03	A4	Supplementary search report drawn up and despatched	Effective date: 20180904
2018-10-03	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20180829BHEP Ipc: A61K 39/395 20060101ALI20180829BHEP
2020-03-04	17Q	First examination report despatched	Effective date: 20200203
2020-10-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-11	18D	Application deemed to be withdrawn	Effective date: 20200616